Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients

References

• Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655
   PubMed Web of Science ®Google Scholar
• Jørgensen TS, Kristensen LE, Christensen R, et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology. 2015;54:2156–2165.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs. Clin Exp Rheumatol. 2016;34:694–697.
   Web of Science ®Google Scholar
• Sergeant JC, Hyrich KL, Anderson J, et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018;20:147. doi:10.1186/s13075-018-1645-5
   PubMed Web of Science ®Google Scholar
• Bluett J, Sergeant JC, MacGregor AJ, et al. Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. Arthritis Res Ther. 2018;20(1):50. doi:10.1186/s13075-018-1544-9
   Web of Science ®Google Scholar
• Uribarri M, Ruiz-Larrañaga O, Arteta D, et al. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project. Clin Exp Rheumatol. 2015;33:699–705.
   PubMed Web of Science ®Google Scholar
• Emery P, Pope JE, Kruger K, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review. Adv Ther. 2018;35(10):1535–1563. doi:10.1007/s12325-018-0757-2
   Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 1988;31(3):315–324. doi:10.1002/art.1780310302
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715
   PubMed Web of Science ®Google Scholar
• Engel-Nitz NM, Ogale S, Kulakodlu M. Use of anti-tumor necrosis factor therapy: a Retrospective Study of monotherapy and adherence to combination therapy with non-biologic disease-modifying anti-rheumatic drugs. Rheumatol Ther. 2015;2(2):127–139. doi:10.1007/s40744-015-0015-x
   Google Scholar
• Weinblatt ME, Fleischmann R, Huizinga TWJ, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology. 2012;51(12):2204–2214. doi:10.1093/rheumatology/kes150
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6):805–811. doi:10.1136/ard.2008.099291
   PubMed Web of Science ®Google Scholar
• Fleischmann R, van Vollenhoven RF, Vencovský J, et al. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatol Ther. 2017;4(1):57–69. doi:10.1007/s40744-017-0060-8
   Web of Science ®Google Scholar
• Berenbaum F, Pham T, Claudepierre P, et al. Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomized Phase III clinical trial. Joint Bone Spine. 2017. doi:10.1016/j.jbspin.2017.01.011
   Web of Science ®Google Scholar
• Iannone F, Semeraro A, Carlino G, et al. Effectiveness of certolizumab-pegol in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis based on the BIOPURE registry: can early response predict late outcomes? Clin Drug Investig. 2019;39(6):565–575. doi:10.1007/s40261-019-00782-9
   PubMed Web of Science ®Google Scholar
• Saraux A, Flipo R-M, Fagnani F, et al. Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. RMD Open. 2020;6(1):e000991. doi:10.1136/rmdopen-2019-000991
   Web of Science ®Google Scholar
• Alten R, Nüßlein HG, Mariette X, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD Open. 2017;3(1):e000345. doi:10.1136/rmdopen-2016-000345
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Miyasaka N, Inui T, et al. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Res Ther. 2017;19:194.
   PubMed Web of Science ®Google Scholar
• Atsumi T, Yamamoto K, Takeuchi T, et al. The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016;75:75–83. doi:10.1136/annrheumdis-2015-207511
   PubMed Web of Science ®Google Scholar
• Smolen JS, Burmester G-R, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763–2774. doi:10.1016/S0140-6736(16)31651-8
   PubMed Web of Science ®Google Scholar